在阵发性睡眠性血红蛋白尿症伴临床显著血管外溶血患者中,在ravulizumab或eculizumab基础上加用danicopan(ALPHA):一项双盲、随机、3期试验
ALPHA是一项国际、3期、随机、双盲、安慰剂对照试验,评估danicopan作为ravulizumab或eculizumab附加疗法用于阵发性睡眠性血红蛋白尿症(PNH)伴临床显著血管外溶血成人患者的疗效与安全性。预设中期分析显示,第12周danicopan组血红蛋白较基线最小二乘均值变化为2.94 g/dL,安慰剂组为0.50 g/dL,最小二乘均值差异2.44 g/dL(95% CI 1.69–3.20;p<0.0001),未报告与研究药物相关的严重不良事件或死亡。
要点
- 第12周danicopan组血红蛋白较基线最小二乘均值变化2.94 g/dL,安慰剂组0.50 g/dL,差异2.44 g/dL(95% CI 1.69–3.20;p<0.0001)。
- danicopan组3级不良事件包括丙氨酸氨基转移酶升高(2/49,4%)、白细胞减少(1/49,2%)、中性粒细胞减少(2/49,4%)等。
- 研究未报告与研究药物相关的严重不良事件或死亡。
核心结论
- Danicopan作为ravulizumab或eculizumab的附加治疗,在第12周显著改善血红蛋白浓度,且无新的安全性问题,提示在PNH伴临床显著血管外溶血患者中具有改善的获益-风险特征。
研究设计与样本
- ALPHA为正在进行中的国际、3期、随机、双盲、安慰剂对照试验,评估danicopan作为ravulizumab或eculizumab附加疗法。
- 纳入年龄≥18岁、PNH伴临床显著血管外溶血(血红蛋白≤9.5 g/dL;绝对网织红细胞计数≥120×10⁹/L)且接受ravulizumab或eculizumab至少6个月的患者。
- 患者按2:1随机分配至danicopan或安慰剂加ravulizumab或eculizumab治疗12周,随机化按输血史、血红蛋白及来自日本的患者分层。
- danicopan初始口服剂量为150 mg每日三次,允许根据临床反应增至200 mg每日三次。
- eculizumab输注剂量水平(每2周)范围为900 mg至1500 mg,ravulizumab(每月或每8周)范围为3000 mg至3600 mg。
主要发现
- 截至数据截止日(2022年6月28日),73例患者随机分配、接受治疗并纳入安全性分析(danicopan组49例,安慰剂组24例)。
- 方案预设的中期疗效分析集包括前63例参与者(danicopan组42例,安慰剂组21例)。
- 第12周时,danicopan联合ravulizumab或eculizumab较安慰剂联合ravulizumab或eculizumab增加血红蛋白(较基线最小二乘均值变化:danicopan组2.94 g/dL[95% CI 2.52–3.36];安慰剂组0.50 g/dL[-0.13–1.12];最小二乘均值差异2.44 g/dL[1.69–3.20];p<0.0001)。
- danicopan组3级不良事件包括丙氨酸氨基转移酶升高(2/49,4%)、白细胞减少(1/49,2%)、中性粒细胞减少(2/49,4%)、胆囊炎(1/49,2%)、COVID-19(1/49,2%)、天冬氨酸氨基转移酶升高(1/49,2%)和血压升高(1/49,2%)。
- 安慰剂组3级不良事件包括贫血(1/24,4%)、血小板减少(1/24,4%)和乏力(1/24,4%)。
关键数值与推荐
- 临床显著血管外溶血定义:血红蛋白≤9.5 g/dL;绝对网织红细胞计数≥120×10⁹/L。
- danicopan初始口服剂量150 mg每日三次,可增至200 mg每日三次。
- eculizumab每2周900 mg至1500 mg;ravulizumab每月或每8周3000 mg至3600 mg。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Symptoms of anaemia due to clinically significant extravascular haemolysis can affect patients with paroxysmal nocturnal haemoglobinuria (PNH) treated with C5 inhibitors (ravulizumab or eculizumab). The aim of this study was to assess the efficacy and safety of danicopan (ALXN2040), an investigational, first-in-class, oral complement factor D inhibitor, as add-on therapy to ravulizumab or eculizumab in patients with PNH and clinically significant extravascular haemolysis. METHODS: ALPHA is an ongoing, international, phase 3, randomised, double-blind, placebo-controlled trial evaluating danicopan as add-on therapy to ravulizumab or eculizumab. Eligible patients were adults (age ≥18 years) with PNH and clinically significant extravascular haemolysis (haemoglobin ≤9·5 g/dL; absolute reticulocyte count ≥120 × 109/L) on ravulizumab or eculizumab for at least 6 months. Patients were randomly assigned (2:1) to danicopan or placebo added to ravulizumab or eculizumab for 12 weeks using an interactive response technology system. Randomisation was stratified based on transfusion history, haemoglobin, and patients enrolled from Japan. The initial oral danicopan dose was 150 mg three times a day; escalation to 200 mg three times a day was permitted based on clinical response. The infusion dose level of eculizumab (every 2 weeks) ranged from 900 mg to 1500 mg, and for ravulizumab (monthly or every 8 weeks) ranged from 3000 mg to 3600 mg. The primary endpoint was change in haemoglobin concentration from baseline to week 12. Here we present the protocol-prespecified interim analysis, planned when approximately 75% of participants were randomly assigned to treatment and completed or discontinued at 12 weeks. This trial is registered with ClinicalTrials.gov (NCT04469465). FINDINGS: Individuals were randomly assigned between Dec 16, 2020, and Aug 29, 2022. At data cutoff (June 28, 2022), 73 individuals were randomly assigned, received treatment, and were analysed for safety (danicopan, n=49; placebo, n=24). The protocol-prespecified interim efficacy analysis set included the first 63 participants (danicopan, n=42; placebo, n=21). At week 12, danicopan plus ravulizumab or eculizumab increased haemoglobin versus placebo plus ravulizumab or eculizumab (least squares mean [LSM] change from baseline: danicopan, 2·94 g/dL [95% CI 2·52 to 3·36]; placebo, 0·50 g/dL [-0·13 to 1·12]; LSM difference, 2·44 g/dL [1·69 to 3·20]; p<0·0001). Grade 3 adverse events in the danicopan group were increased alanine aminotransferase (two [4%] of 49 patients), leukopenia (one [2%]), neutropenia (two [4%]), cholecystitis (one [2%]), COVID-19 (one [2%]), increased aspartate aminotransferase (one [2%]), and increased blood pressure (one [2%]), and in the placebo group were anaemia (one [4%] of 24 patients), thrombocytopenia (one [4%]), and asthenia (one [4%]). The serious adverse events reported in the danicopan group were cholecystitis (one [2%] patient) and COVID-19 (one [2%]) and in the placebo group were anaemia and abdominal pain, both in one (4%) patient. There were no serious adverse events related to study drug or deaths reported in the study. INTERPRETATION: These primary efficacy and safety results show that danicopan as add-on treatment to ravulizumab or eculizumab significantly improved haemoglobin concentrations at week 12 with no new safety concerns, suggesting an improved benefit-risk profile in patients with PNH and clinically significant extravascular haemolysis. FUNDING: Alexion, AstraZeneca Rare Disease.
引用
- Lee JW, Griffin M, Kim JS, et al. Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial. Lancet Haematol. 2023. PMID: 38030318. doi:10.1016/S2352-3026(23)00315-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。